emerging glp-1 gip obesity treatments 2025 Q&A: Long-term success of therapies hinges on more than just a prescription GLP-1 receptor agonists and next-generation

Patients eligible to enter the trial were 50 years of age or older and had established, stable, CV, cerebrovascular, peripheral artery disease, CKD or NYHA class II and III heart failure or were 60 years of age or older and had other specified risk factors for CV disease

Some analyses suggest that lean mass loss can constitute 20% to 50% of the total weight reduction in certain trials

High homocysteine levels are also associated with neural tube defects, placental abruption, pre-term birth, and recurrent pregnancy loss.[ref] How is high homocysteine defined

Haithcock, E

How do they work and how are they given

Olive-derived elenolic acid surpasses metformin and rivals GLP-1 therapies